Working… Menu

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03081910
Recruitment Status : Recruiting
First Posted : March 16, 2017
Last Update Posted : October 5, 2021
Center for Cell and Gene Therapy, Baylor College of Medicine
Houston Methodist Hospital, TX
Information provided by (Responsible Party):
Rayne Rouce, Baylor College of Medicine

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2024
Estimated Study Completion Date : September 1, 2039